AstraZeneca stock consolidates as STRIDE regimen with lenvatinib improves survival in liver cancer

Traders Union
All News
Financial News
AstraZeneca falls 0.66% to GBX13,345.60

Highlights

AstraZeneca’s STRIDE regimen plus lenvatinib and TACE showed significant progression-free survival benefit in Phase 3 EMERALD-3 for unresectable HCC.
Positive Phase 3 results for anselamimab in the CARES program advance AstraZeneca’s specialty therapeutics pipeline in rare diseases.
AZN remains under technical selling pressure, trading below key moving averages with projected sideways movement in the GBX 13,150.00–13,550.00 range barring a decisive breakout.

Late-stage oncology gains offset by persistent selling pressure

Phase 3 results from the EMERALD-3 trial showed that AstraZeneca's STRIDE regimen, in combination with lenvatinib and TACE, significantly improved progression-free survival among patients with unresectable hepatocellular carcinoma who are eligible for embolization. This data supports the clinical efficacy of the regimen and advances AstraZeneca's late-stage oncology portfolio, with potential to expand its addressable patient population over time. Additional positive Phase 3 data for anselamimab in a rare disease setting from the CARES program highlights progress across specialty therapeutics. The company also confirmed its issued share capital at 1,551,009,750 ordinary shares as of May 31, 2026, underscoring transparency in its capital structure, though price action has remained under broader selling pressure.

Robust downtrend as technicals stay oversold and volatility rises

AZN is currently positioned below the SMA-20 (GBX 13,694.19), SMA-50 (GBX 14,180.04), and SMA-200 (GBX 13,502.88) levels, with the Ichimoku Kijun at GBX 13,178.00 providing immediate support just beneath the current price. The session's range has spanned GBX 13,336.00 to GBX 13,432.00 on moderate volatility. Technical momentum remains negative, with MACD signaling a strong sell and the ADX confirming a robust downtrend. Oscillators including RSI, Stoch RSI, and CCI are in oversold territory, while BBP indicates clear seller dominance. The Awesome Oscillator is neutral on D1 but negative across intraday timeframes, underscoring continued downside momentum. However, persistent oversold readings suggest the potential for a short-term technical rebound.

Sideways trend expected as oversold signals temper further declines

Over the next five trading days, AZN is expected to trade within a volatility band of GBX 13,150.00 to GBX 13,550.00, in line with typical weekly swings for a large-cap stock. The baseline scenario anticipates sideways movement within this corridor, as oversold conditions moderate further downside. Should the price break above the SMA-20, an upward move toward GBX 13,700.00 is possible. Conversely, a bearish scenario could unfold if AZN drops below the Ichimoku Kijun at GBX 13,178.00, with risk accelerating toward the GBX 13,000.00 support.

Anton Kharitonov, expert at Traders Union, sees AstraZeneca’s positive trial updates as good for its long-term clinical pipeline. However, he notes that persistent technical weakness and seller dominance outweigh near-term optimism. For now, cautious sentiment continues to dominate as shares remain below key moving averages. "Unless AZN can reclaim the GBX 13,700.00 zone, I see no technical reason to position for upside."

Earlier, analysts noted that AstraZeneca shares were under sustained selling pressure despite progress in its drug development pipeline and strategic partnerships. The latest oversold signals amid robust negative momentum reinforce this cautious stance, making AZN’s performance around the Ichimoku Kijun at GBX 13,178.00 a pivotal level for traders to monitor for potential downside acceleration.

Source of Data: AZN Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.